ArticleScientific reports2025
Disrupted mucosal vascular barrier in eosinophilic esophagitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
- Any role for respiratory allergens in IBS symptoms? From pathogenetic hypothesis to therapeutic implications.Frontiers in allergy · 2026Article
- The Immune Architecture of Eosinophilic Esophagitis: Mechanisms, Therapeutic Targets, and Precision Management.ImmunoTargets and therapy · 2026Review
- Probing the gut barrier: epithelial permeability as a dynamic marker in eosinophilic gastroenteritis via pCLE.Therapeutic advances in gastrointestinal endoscopyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Esophageal barrier has been investigated until now on the epithelial side only. Gut vascular barrier dysfunction has been recently implicated in a number of immune-mediated gastrointestinal disorders. We here characterized the esophageal vascular barrier (EVB) in eosinophilic esophagitis (EoE). Probe-based confocal laser endomicroscopy (pCLE) was performed in two EoE and two reflux esophagitis (RE) patients. The vascular barrier marker plasmalemma vesicle-1 (PV-1) was investigated as a measure of barrier disruption, by both immunohistochemistry and qPCR, in esophageal biopsies of 16 patients with EoE, 15 with RE, and 15 healthy controls (HC). In EoE, but not RE, pCLE revealed leakage of the EVB, which was restored in one patient after dupilumab treatment. PV-1 was significantly increased in EoE in comparison to RE and HC, both in terms of protein and transcript levels, supporting vascular leakage. EVB is disrupted in active EoE. Further studies are needed to understand the diagnostic and pathogenic implications of this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.